Incidence of giant cell arteritis is associated with COVID-19 prevalence: A population-level retrospective study.
COVID-19
Epidemiology
Giant cell arteritis
Pathogenesis
Rheumatology
Vasculitis
immunology
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
08
12
2022
revised:
27
06
2023
accepted:
30
06
2023
medline:
24
7
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
Following the first wave of the COVID-19 pandemic, it was observed that giant cell arteritis (GCA) diagnoses increased at the Royal National Hospital for Rheumatic Diseases (RNHRD) in Bath, UK. This finding may support the viral aetiology hypothesis of GCA. Better understanding of the causes of GCA may help improve diagnostic and treatment strategies leading to better outcomes for patients. The study aims to estimate the local incidence of GCA during the early COVID-19 pandemic (2020-2021) and compare it to pre-pandemic (2015-2019) data. This study will also evaluate the temporal relationship between COVID-19 infections and GCA diagnoses. Annual incidence rates of GCA were calculated between 2015 and 2021. Local COVID-19 prevalence was estimated by measuring the number of hospital beds taken up by COVID-19 positive patients. Poisson statistics were used to compare the annual mean incidence of GCA between 2019 and 2020, and Granger causality tested the temporal relationship between COVID-19 prevalence and GCA incidence. There were 60 (95% confidence interval [CI] 46-77) GCA diagnoses made in 2020 compared to 28 (CI 19-41) in 2019 ( The incidence of GCA in Bath was significantly increased in 2020 and 2021 compared to 2015-2019. The lag period between peaks was 40-45 days, suggesting that the COVID-19 virus may be a precipitating factor for GCA. More work is currently underway to interrogate the causal relationship between these two diseases.
Sections du résumé
Background
UNASSIGNED
Following the first wave of the COVID-19 pandemic, it was observed that giant cell arteritis (GCA) diagnoses increased at the Royal National Hospital for Rheumatic Diseases (RNHRD) in Bath, UK. This finding may support the viral aetiology hypothesis of GCA. Better understanding of the causes of GCA may help improve diagnostic and treatment strategies leading to better outcomes for patients.
Objectives
UNASSIGNED
The study aims to estimate the local incidence of GCA during the early COVID-19 pandemic (2020-2021) and compare it to pre-pandemic (2015-2019) data. This study will also evaluate the temporal relationship between COVID-19 infections and GCA diagnoses.
Methods
UNASSIGNED
Annual incidence rates of GCA were calculated between 2015 and 2021. Local COVID-19 prevalence was estimated by measuring the number of hospital beds taken up by COVID-19 positive patients. Poisson statistics were used to compare the annual mean incidence of GCA between 2019 and 2020, and Granger causality tested the temporal relationship between COVID-19 prevalence and GCA incidence.
Results
UNASSIGNED
There were 60 (95% confidence interval [CI] 46-77) GCA diagnoses made in 2020 compared to 28 (CI 19-41) in 2019 (
Conclusion
UNASSIGNED
The incidence of GCA in Bath was significantly increased in 2020 and 2021 compared to 2015-2019. The lag period between peaks was 40-45 days, suggesting that the COVID-19 virus may be a precipitating factor for GCA. More work is currently underway to interrogate the causal relationship between these two diseases.
Identifiants
pubmed: 37483752
doi: 10.1016/j.heliyon.2023.e17899
pii: S2405-8440(23)05107-1
pmc: PMC10359857
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e17899Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
Références
Semin Arthritis Rheum. 2020 Oct;50(5):1040-1048
pubmed: 32911281
Ann Rheum Dis. 2021 Jun;80(6):e89
pubmed: 32769152
Arthritis Rheum. 1995 Mar;38(3):374-80
pubmed: 7880192
Clin Exp Rheumatol. 2021 Mar-Apr;39 Suppl 129(2):199-200
pubmed: 33822699
Front Immunol. 2022 Jun 15;13:923582
pubmed: 35784327
Ann Rheum Dis. 2006 Aug;65(8):1093-8
pubmed: 16414971
Heliyon. 2020 Oct 19;6(10):e05208
pubmed: 33102842
Rheumatology (Oxford). 2012 May;51(5):926-31
pubmed: 22258386
RMD Open. 2017 Aug 29;3(2):e000531
pubmed: 29225921
Int J Mol Sci. 2020 Dec 06;21(23):
pubmed: 33291346
Neuroimage. 2011 Sep 15;58(2):323-9
pubmed: 20202481
J Rheumatol. 2021 Jul;48(7):1053-1059
pubmed: 33060304
J Exp Med. 2004 Jan 19;199(2):173-83
pubmed: 14734523
Rheumatology (Oxford). 2021 Dec 24;61(1):146-153
pubmed: 33742665
Rheumatol Adv Pract. 2020 Dec 01;4(2):rkaa067
pubmed: 33364547
J Autoimmun. 2008 Nov;31(3):252-6
pubmed: 18502610
Arthritis Rheum. 1990 Aug;33(8):1074-87
pubmed: 1975173
J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):214-22
pubmed: 10025748
J Rheumatol. 2016 Jul;43(7):1393-9
pubmed: 27134245
Mol Immunol. 2019 Jan;105:107-115
pubmed: 30502718
J Rheumatol. 2021 Feb;48(2):251-257
pubmed: 32414956